[{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ahmed M. Hamdy M.D.", "age": 59, "title": "Co-Founder & Chairman", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 1130932, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raquel E. Izumi Ph.D.", "age": 54, "title": "Co-Founder, Acting CEO, Secretary & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1032753, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom C. Thomas J.D.", "age": 64, "title": "Consultant", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 858983, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander A. Seelenberger M.B.A.", "age": 45, "title": "Consultant", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 854333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Byrd M.D.", "title": "Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Haas", "age": 59, "title": "Acting CFO, VP of Finance & Corporate Controller", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Lerchen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabriela  Jairala", "title": "VP of Investor Relations & Corporate Communications and Chief of Staff", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Quarford M.B.A.", "title": "Vice President of Quality Operations & Compliance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Merrick SPHR", "title": "Senior Director of People & Culture and Head of Human Resource", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.2562, "open": 0.26, "dayLow": 0.2306, "dayHigh": 0.2962, "regularMarketPreviousClose": 0.2562, "regularMarketOpen": 0.26, "regularMarketDayLow": 0.2306, "regularMarketDayHigh": 0.2962, "payoutRatio": 0.0, "beta": 1.394, "forwardPE": -0.41044775, "volume": 1550327, "regularMarketVolume": 1550327, "averageVolume": 1140632, "averageVolume10days": 1034390, "averageDailyVolume10Day": 1034390, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 1439427, "fiftyTwoWeekLow": 0.22, "fiftyTwoWeekHigh": 19.88, "fiftyDayAverage": 0.81098, "twoHundredDayAverage": 6.937745, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -3547573, "profitMargins": 0.0, "floatShares": 4940477, "sharesOutstanding": 5234280, "sharesShort": 137204, "sharesShortPriorMonth": 191883, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.026199998, "heldPercentInsiders": 0.041149996, "heldPercentInstitutions": 0.04065, "shortRatio": 0.1, "shortPercentOfFloat": 0.0272, "impliedSharesOutstanding": 5234280, "bookValue": 1.216, "priceToBook": 0.22615133, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -30074000, "trailingEps": -15.85, "forwardEps": -0.67, "lastSplitFactor": "1:20", "lastSplitDate": 1738022400, "enterpriseToEbitda": 0.122, "52WeekChange": -0.98417723, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 0.275, "targetHighPrice": 200.0, "targetLowPrice": 200.0, "targetMeanPrice": 200.0, "targetMedianPrice": 200.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 4987000, "totalCashPerShare": 0.953, "ebitda": -29011000, "totalDebt": 0, "quickRatio": 1.141, "currentRatio": 1.214, "returnOnAssets": -1.38543, "returnOnEquity": -4.31292, "freeCashflow": -12235375, "operatingCashflow": -26127000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VINC", "language": "en-US", "region": "US", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "firstTradeDateMilliseconds": 1590586200000, "hasPrePostMarketData": false, "regularMarketChange": 0.0188, "regularMarketDayRange": "0.2306 - 0.2962", "fullExchangeName": "Nasdaq", "averageDailyVolume3Month": 1140632, "fiftyTwoWeekLowChange": 0.055000007, "fiftyTwoWeekLowChangePercent": 0.25000003, "fiftyTwoWeekRange": "0.22 - 19.88", "fiftyTwoWeekHighChange": -19.605, "fiftyTwoWeekHighChangePercent": -0.986167, "fiftyTwoWeekChangePercent": -98.417725, "earningsTimestamp": 1743105600, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "marketState": "CLOSED", "shortName": "Vincerx Pharma, Inc. Common Stock", "longName": "Vincerx Pharma, Inc. Common Stock", "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -15.85, "epsForward": -0.67, "fiftyDayAverageChange": -0.53598, "fiftyDayAverageChangePercent": -0.66090405, "twoHundredDayAverageChange": -6.662745, "twoHundredDayAverageChangePercent": -0.9603617, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2025-04-21", "prevName": "Vincera Pharma, Inc.", "nameChangeDate": "2025-04-18", "cryptoTradeable": false, "corporateActions": [{"header": "New Listing", "message": "VINC is newly listed on Nasdaq effective Apr. 21, 2025", "meta": {"eventType": "NEW_LISTING", "dateEpochMs": 1745208000000, "exchange": "Nasdaq"}}], "regularMarketTime": 1744747200, "exchange": "NAS", "messageBoardId": "finmb_690173412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 7.33803, "regularMarketPrice": 0.275, "displayName": "Vincerx Pharma", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]